ASSESSMENT OF TWO STRATEGIES OF NEORAL® ADMINISTRATION, EARLY VERSUS DELAYED, ON RENAL FUNCTION AND EFFICACY IN DE NOVO RENAL TRANSPLANT PATIENTS RECEIVING MYFORTIC®, STEROIDS AND ANTI-IL2R ANTIBODIES: 6 MONTHS INTERIM RESULTS OF A RANDOMIZED, MULTICENTRE, OPEN, PROSPECTIVE CONTROLLED STUDY